Introduction: Spasm of the human internal mammary artery (HIMA) is a rare but life-threatening complication after coronary artery bypass grafting (CABG). The reversal of this vasospasm is often challenging, and the most effective therapy is not well defined. The present study was aimed to investigate vasorelaxant effect of nicorandil, K+ channel opener, on the HIMA and to define the role of different K+ channel subtypes in nicorandil action on this blood vessel. Patients (or Materials) and Methods: Discarded segments of HIMA were collected from patients undergoing CABG and studied in organ baths. HIMA rings were precontracted with phenylephrine (10 µM) followed by cumulatively adding increasing doses of nicorandil. The endothelium was removed mechanically. Results: Nicorandil (0.001 µM-300 µM) induced a concentrationdependent relaxation of HIMA rings precontracted by phenylephrine. Glibenclamide (10 μ M), a highly selective blocker of ATP-sensitive K+ (K ATP ) channels, partially inhibited relaxation of HIMA induced by nicorandil. Tetraethylammonium (TEA, 1 mM), a nonselective blocker of Ca 2+ -activated K+ (K Ca ) channels, as well as iberiotoxin (100 nM), a most selective blocker of large-conductance K Ca (BK Ca ) channels, partly antagonized relaxation of HIMA. A nonselective blocker of voltage-gated K+ (K V ) channels, 4-aminopyridine (4-AP, 0.5 mM), as well as margatoxin (10 nM), a potent inhibitor of K V 1.3 channels, did not significantly modify the nicorandil-induced relaxation of HIMA. Conclusion: The results from our study demonstrate that, in HIMA, nicorandil has a potent vasorelaxant effect which is endotheliumindependent. It seems that mechanism of this relaxation includes KATP and 4-AP-sensitive K+ channels located in the smooth muscle of HIMA. Disclosure of Interest: None declared.
PE during incubation with control solutions (methyl acetate: BEL solvent; Krebs buffer or R-BEL; PE alone: 9.8 [2.5] mN; PE with controls: 7.1 [2.0] mN: P = 0.012, Wilcoxon). Incubation with S-BEL had not effect on contraction to KCl 60 mM compared with incubation with controls (methyl acetate, Krebs buffer, or R-BEL]. The post-S-BEL washout contractile response to PE was abolished (PE post-S-BEL: -1.2 [0.7] mN; P = 0.002, Friedman test; P = 0.028 vs pre-S-BEL PE response). Contraction to PE after washout of controls was similar to initial PE responses. Effects were similar for S-BEL 25 uM versus S-BEL 12.5 uM on contractile responses to PE. Propranolol (50 mM) prevented contraction to phenylephrine alone and the early effect of S-BEL to enhance contractile responses to PE. Conclusion: S-BEL has complex, biphasic, time-dependent effects on PE-mediated arterial constriction. Propranolol is both a betaadrenergic antagonist and inhibitor of PAP-1. Although S-BEL selectively inhibits iPLA2β , our findings suggest that other targets may also contribute to modulation of PE-dependent arterial contraction. Disclosure of Interest: None declared.
PP092-ChaNgeS iN VaSCular reaCTiViTy CauSed by aNgioTeNSiN ii iN iSolaTed VeSSelS of raT aorTa iN a model of hyPerTeNSioN
E.M. Lopez-Calderon 1* ; L.N. Acevedo-Villavicencio 1 ; G.C. Villanueva-Lopez 1 ; E. Lara-Padilla 1 ; G. Guevara-Balcazar 1 ; E. Hong-Chong 2 ; and M.C. Castillo-Hernandez 1 1 Seccion de estudios de Posgrado e Investigacion, Escuela Superior de Medicina del Instituto Politecnico Nacional; and 2 Farmacobiologia, Centro de Investigacion y Estudios Avanzados, sede Sur, Mexico City, Mexico Introduction: Hypertension (HBP) is a disease with high morbidity and mortality worldwide and is a major etiological factor in heart and vascular diseases. An important regulatory mechanism of blood pressure (BP) is the renin angiotensin system (RAS). In fact, all the firstline drugs for the treatment of hypertension act on some component of the RAS. However, these treatments frequently lead to the development of changes in morphology and physiology characterized by vascular complications. It is therefore necessary to consider adjuvant therapies to improve the outcome of treatments and therefore in the quality of life of patients with HBP. A therapy that has been shown to improve the clinical condition of patients with HBP is hyperbaric oxygenation (HBO), in which the patient is subject to a pressure of 2 atmospheres absolute with an oxygen concentration of 100%. This therapy has been shown to improve vascular smooth muscle relaxation, although the mechanism of action has not yet been specified. The aim of this study is to examine the role of the RAS in the relaxation of vessels in hypertensive rats that is produced by HBO. Patients (or Materials) and Methods: Male Wistar rats were used (340 ± 20 g) at standard conditions (light/dark cycle, water and food ad libitum), and hypertension was induced by a previously described surgical method (PAGE). Stable hypertension was established at 7 days' postsurgery (for plethysmographic method). On the eighth day, HBO therapy began, and was carried out 5 days per week for 4 weeks. Rats were sacrificed at the end of treatment, obtaining thoracic and abdominal aorta. The endothelium was removed by a mechanical method, aortic rings were mounted, and concentration response curves were constructed according to increasing doses of ANG II for all groups with and without HBO. The results are analyzed with 2-way ANOVA and post hoc Von Ferroni. Results: Diastolic pressure was found to be 150 (10) mm Hg, consistent with the definition of hypertension. The angiotesin contractile response was lower in the groups of rats treated with HBO, compared with the 2 control groups (untreated and SHAM animals).
Conclusion: HBO therapy reduced vascular reactivity in both segments of the hypertensive rat aorta. This suggests that HBO could possibly be used with hypertensive patients to reduce the use of drugs in therapy. Disclosure of Interest: None declared. Introduction: Congestive heart failure (CHF), caused by ischemic cardiomyophaty and diabetes II-type, is a devastating clinical problem.The aim of this study was highlight several advances in the understanding of molecular pathways involved in cardiac hypertrophy, inflammatory signaling, and oxidant stress that may play a key role in altering transcriptional regulatory networks regulating adaptation or maladaptation, and consequently, the transition to overt HF. Patients (or Materials) and Methods: A total of 56 patients aged 53 (6) years, with ischemic cardiomyophaties (ICMP) accompanied with the diabetes II-type were included in the study. Entry criteria's were: the left ventricular ejection fraction (LVEF) < 40% and mild LV dilatation, symptoms of CHF for the last 2 months, at least. All patients including in the study were randomized into 2 groups; control received standard therapy (digoxin 0.025 mg per day, inhibitor of ACE and a diuretic, n = 29) and the main one (n = 30) an inhibitor of ACE, a diuretic, and Adenocin (2 ampoules diluted in 50-100 mL of saline in infused IV). There were no significant differences in baseline characteristics (demographic and anamnesis) between groups. Plasma levels of cytokines (interleukine-1β [L-1β ], tumor necrosis factor [TNF-a]), redox-potential NAD/NADH, superoxide anion production, activities of superoxide dismutase (SOD), and catalase (CT) were determined. Results: It has been shown that in the control group, the functional class (FC) of CHF by NYHA decreased by 12%, the dyspnea by 49%, lung congestion by 78%, hepatomegaly by 70%, and peripheral edema improved by 45%. The total CHF score improved by 52%. In the main group, the FC of CHF improved by 25%, dyspnea and lung congestion disappeared completely, hepatomegaly improved by 74%, peripheral edema -by 88%. The total score improved by 67%. In the group receiving Adenocin, LVEF improved by 16% (from 26% to 42%), stroke volume improved by 28%. Hence, the optimal treatment of CHF would be achieved through increase in the energy supply: redox-potential NAD/NADH increased by 34%, the content of pyridine nucleotide in the plasma by 40%. The activity of the marker of hyperactivation of the system of reactive oxygen production decreased by 48% and activities of SOD and CT increased by 45% and 60%, respectively. Treatment with Adenocin leads to a markedly improve of the state of immune system and as a result the content of proinflammatory cytokines, IL-1 β and TNF-a decreased by 49 and 38%, respectively. Conclusion: The modern approach to treatment of HF is multidisciplinary, given that mandatory multiorgan attention is required to ensure early good outcome in these high-risk patients with ICMP and diabetes II-type. From the present results, it is evident that Adenocin cessates cardiac remodeling during the development of cardiac hypertrophy and resrores functional activity of the myocardium. Disclosure of Interest: None declared.
PP094-TargeTS of

PP100-PoTeNTial of NaTTokiNaSe aS aN aNTiThromboTiC & fibriNolyTiC ageNT
T. Shirole 1* ; S.L. Sharma 2 ; and A.G. Jagtap 1 1 Pharmacology, Bombay College of Pharmacy; and 2 Zytex India Pvt Ltd, Mumbai, India Introduction: Thrombosis is 1 of the major causes of death worldwide. Atherothrombotic diseases such as myocardial or cerebral infarction are serious consequences of the thrombus formed in blood vessels. Nattokinase is new fibrinolytic enzyme with a molecular weight of 27 728 Da that cleaves directly cross-linked fibrin in vitro. In this study, we investigated the effect of nattokinase supplementation on thrombus formation using different animal models.
Patients (or Materials) and Methods:
To study the fibrinolytic activity, in vitro clot dissolution assay was done in which clot was formed in helix and then kept in contact with different concentrations of nattokinase and streptokinase (standard drug) and its clot dissolution property was studied. Further it was studied for its antithrombotic activity in venous thrombosis. Rats were pretreated orally for 7 days with Nattokinase (100 and 200 mg/kg). One hour after the last dose, stasis was developed in the inferior vena cava in rats, and its activity was intensified with the help of ferric chloride. It was also studied for its antithrombotic activity in arterial thrombosis using arteriovenous shunt-induced thrombosis in rats. In this rats were pretreated orally for 7 days with Nattokinase (100 and 200 mg/kg) and on last day 1 hour after last dose thrombosis was induced by arterio-venous shunt. In both the above studies, % inhibition of thrombus formation was calculated. Because hemorrhage is an important side effect of antithrombotic and thrombolytic therapies, the drug was studied for its effect on hemorrhage using rat tail transaction method. Here, effect of 7 days pretreatment of 2 doses of nattokinase (100 and 200 mg/kg) on hemorrhage was studied. Results: In in vitro clot dissolution assay, there was significant and dose-dependent clot dissolution with different concentration of nattokinase. Maximum activity, 94.43 % inhibition, was seen in 3000ug/ mL concentration which was comparable with 1000 IU of streptokinase. In venous thrombosis model, it showed significant and dosedependent inhibition of thrombus formation as indicated by decrease in weight of thrombus. Antithrombotic potential of nattokinase at the highest dose (200 mg/kg) showed 45.431% inhibition with respect to saline control group. In arterio-venous shunt ,it showed no significant inhibition of thrombus formation on thrombogenic surface. In the rat tail transaction model, both the doses of nattokinase (100 and 200 mg/kg) has significantly increased the bleeding time with not much effect on blood loss. Also, the platelet MDA was significantly decreased in both groups treated with 100 and 200 mg/kg of nattokinase.
Conclusion:
The results of various in vitro and in vivo models studied indicate that nattokinase has a good potential as an antithrombotic and fibrinolytic agent. Disclosure of Interest: None declared.
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M. Lopez-Calderon 1* ; L.N. Acevedo-Villavicencio 1 ; G.C. Villanueva-Lopez 1 ; E. Lara-Padilla 1 ; G. Guevara-Balcazar 1 ; E. Hong-Chong 2 ; and M.C. Castillo-Hernandez 1 1 Seccion de estudios de Posgrado e Investigacion, Escuela Superior de Medicina del Instituto Politecnico Nacional; and 2 Farmacobiologia, Centro de Investigacion y Estudios Avanzados, sede Sur, Mexico City, Mexico Introduction: High blood pressure (HBP) is a disease with high morbidity and mortality worldwide and is considered 1 of the main etiologic factors of multiple cardiac pathologies like cardiac hypertrophy, myocardial infarction, among others. One of the regulatory mechanisms of blood pressure is the renin angiotensin system (RAS), so much so that the first-line drugs in the treatment of hypertension are directed to some of the components of the RAS. However, these treatments frequently lead to the development of changes in morphology and physiology characterized by vascular complications .It is therefore necessary to consider adjuvant therapies to improve the outlook and quality of life of patients with HBP. A therapy that has been shown clinically to improve the condition of patients with HBP is hyperbaric oxygenation (HBO), which consists in subjecting a subject at a pressure > 2 atmospheres absolute with an 100% oxygen. This therapy has been shown to improve vascular smooth muscle relaxation, although the mechanism of action has not yet been specified.
